Company Profile
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Latest News
Cathie Wood makes $20.5M bet on sliding tech stock
Why Wall Street Is Growing More Cautious on Biohaven (BHVN)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.xenon-pharma.com |
| Audit Risk | 5 |
| Board Risk | 1 |
| Overall Risk | 4 |
| Market Cap | 6.32B |
| Forward P/E | -13.01 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -4.7 |
| Forward EPS | -5.03 |
| Book Value | 7.27 |
| Price-to-Book | 9 |
| Enterprise-to-EBITDA | -12.77 |
| Short Ratio | 3.26 |
| Earnings Date | 08/10/2026 |
| Earnings Call Date | 05/07/2026 |
| Earnings Average | -1.16 |
| Earnings Low | -1.46 |
| Earnings High | -0.92 |
| Revenue Average | 937,500 |
| Revenue Low | 0 |
| Revenue High | 15.00M |